BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 19147766)

  • 1. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.
    Russo AL; Kwon HC; Burgan WE; Carter D; Beam K; Weizheng X; Zhang J; Slusher BS; Chakravarti A; Tofilon PJ; Camphausen K
    Clin Cancer Res; 2009 Jan; 15(2):607-12. PubMed ID: 19147766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide.
    Kil WJ; Cerna D; Burgan WE; Beam K; Carter D; Steeg PS; Tofilon PJ; Camphausen K
    Clin Cancer Res; 2008 Feb; 14(3):931-8. PubMed ID: 18245557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
    Calabrese CR; Almassy R; Barton S; Batey MA; Calvert AH; Canan-Koch S; Durkacz BW; Hostomsky Z; Kumpf RA; Kyle S; Li J; Maegley K; Newell DR; Notarianni E; Stratford IJ; Skalitzky D; Thomas HD; Wang LZ; Webber SE; Williams KJ; Curtin NJ
    J Natl Cancer Inst; 2004 Jan; 96(1):56-67. PubMed ID: 14709739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
    Gupta SK; Mladek AC; Carlson BL; Boakye-Agyeman F; Bakken KK; Kizilbash SH; Schroeder MA; Reid J; Sarkaria JN
    Clin Cancer Res; 2014 Jul; 20(14):3730-41. PubMed ID: 24838527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
    Tentori L; Portarena I; Torino F; Scerrati M; Navarra P; Graziani G
    Glia; 2002 Oct; 40(1):44-54. PubMed ID: 12237842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.
    Thomas HD; Calabrese CR; Batey MA; Canan S; Hostomsky Z; Kyle S; Maegley KA; Newell DR; Skalitzky D; Wang LZ; Webber SE; Curtin NJ
    Mol Cancer Ther; 2007 Mar; 6(3):945-56. PubMed ID: 17363489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
    Tentori L; Leonetti C; Scarsella M; D'Amati G; Vergati M; Portarena I; Xu W; Kalish V; Zupi G; Zhang J; Graziani G
    Clin Cancer Res; 2003 Nov; 9(14):5370-9. PubMed ID: 14614022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.
    Miknyoczki S; Chang H; Grobelny J; Pritchard S; Worrell C; McGann N; Ator M; Husten J; Deibold J; Hudkins R; Zulli A; Parchment R; Ruggeri B
    Mol Cancer Ther; 2007 Aug; 6(8):2290-302. PubMed ID: 17699724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma.
    Barazzuol L; Jena R; Burnet NG; Meira LB; Jeynes JC; Kirkby KJ; Kirkby NF
    Radiat Oncol; 2013 Mar; 8():65. PubMed ID: 23510353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
    Wang W; Duan B; Zeng L
    Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential.
    Dungey FA; Löser DA; Chalmers AJ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1188-97. PubMed ID: 18954712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.
    McEllin B; Camacho CV; Mukherjee B; Hahm B; Tomimatsu N; Bachoo RM; Burma S
    Cancer Res; 2010 Jul; 70(13):5457-64. PubMed ID: 20530668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90.
    Dungey FA; Caldecott KW; Chalmers AJ
    Mol Cancer Ther; 2009 Aug; 8(8):2243-54. PubMed ID: 19671736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
    Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
    BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiosensitization effect of poly(ADP-ribose) polymerase inhibition in cells exposed to low and high liner energy transfer radiation.
    Hirai T; Shirai H; Fujimori H; Okayasu R; Sasai K; Masutani M
    Cancer Sci; 2012 Jun; 103(6):1045-50. PubMed ID: 22404155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma.
    Weaver AN; Cooper TS; Rodriguez M; Trummell HQ; Bonner JA; Rosenthal EL; Yang ES
    Oncotarget; 2015 Sep; 6(29):26995-7007. PubMed ID: 26336991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
    Daniel RA; Rozanska AL; Thomas HD; Mulligan EA; Drew Y; Castelbuono DJ; Hostomsky Z; Plummer ER; Boddy AV; Tweddle DA; Curtin NJ; Clifford SC
    Clin Cancer Res; 2009 Feb; 15(4):1241-9. PubMed ID: 19174487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
    Miknyoczki SJ; Jones-Bolin S; Pritchard S; Hunter K; Zhao H; Wan W; Ator M; Bihovsky R; Hudkins R; Chatterjee S; Klein-Szanto A; Dionne C; Ruggeri B
    Mol Cancer Ther; 2003 Apr; 2(4):371-82. PubMed ID: 12700281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
    Balvers RK; Lamfers ML; Kloezeman JJ; Kleijn A; Berghauser Pont LM; Dirven CM; Leenstra S
    J Transl Med; 2015 Feb; 13():74. PubMed ID: 25886061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
    Murai J; Zhang Y; Morris J; Ji J; Takeda S; Doroshow JH; Pommier Y
    J Pharmacol Exp Ther; 2014 Jun; 349(3):408-16. PubMed ID: 24650937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.